



FOR IMMEDIATE RELEASE

**Immgenuity Inc., Announces the Appointment of Jesse Milan, Jr., JD to its Scientific Advisory Board**

Dover, Delaware, April 27, 2023 – Immgenuity, a biotech company focused on developing innovative immunotherapies, announced today that Jessie Milan, Jr. has joined its Scientific Advisory Board. In his service to the company, Mr. Milan will not be acting on behalf of any organization nor representing any organization. His advice and guidance will be his own.

Jesse Milan, Jr., JD is a highly respected attorney and a tireless community advocate. Mr. Milan is a recognized national and international expert on HIV/AIDS policies and programs. He brings over 30 years in executive roles in public and private sectors, including in government, not-for-profit, academic, and faith organizations. During his long career, Mr. Milan has directed multi-million-dollar budgets and programs for federal, state, local, and global health agencies. Mr. Milan's exceptional record of public service includes serving currently on the Scientific Advisory Board for the President's Emergency Plan for AIDS Relief (PEPFAR), on the Infectious Disease Board of the American Board of Internal Medicine, and on the board of AVAC (AIDS Vaccine Advocacy Coalition). In 2020, he delivered the opening address to the American Medical Students Association conference and the closing address for HRSA for the 30th anniversary of the Ryan White Program. He is an officer of the board of directors of Funders Concerned About AIDS (FCAA) and serves on the Dean's Advisory Council for the UNC Gillings School of Global Public Health. Mr. Milan chaired the CDC/HRSA Advisory Committee on HIV and STD Prevention and Treatment for five years. In 2007 he was designated a Fulbright Senior Specialist in Global HIV/AIDS. Mr. Milan currently serves as President and CEO of AIDS United.

"We are thrilled to welcome Jesse to our Scientific Advisory Board. His expertise in public health policy and advocacy, as well as his commitment to improving health outcomes for underserved communities, will be invaluable to our team as we continue to develop innovative solutions to combat infectious diseases," said Dr. Sateesh Apte, CEO of Immgenuity.

"I am very enthusiastic to join Immgenuity's Scientific Advisory Board and to work with such a talented team of scientists and researchers." I believe that Immgenuity's innovative approach to HIV has the potential to make a significant impact on public health, and I look forward to contributing to its efforts." said Jesse Milan, Jr.

**About Immgenuity, Inc.**

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company's lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a

team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

### **About IMTV014**

Immgenuity's immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as "salvage therapy" in the multidrug resistant population.

Contact: Media Relations: [media@immgenuity.com](mailto:media@immgenuity.com) (302) 321-5844

### **Forward Looking Statements:**

This press release contains "forward-looking statements" within the meaning of federal securities law, including statements concerning the company's outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.